Soligenix announces top-line results of the phase 2a study of sgx302 (synthetic hypericin) in patients with mild-to-moderate psoriasis

Clinical success achieved in second cohort of patients princeton, n.j. , jan. 4, 2024 /prnewswire/ -- soligenix, inc. (nasdaq: sngx) (soligenix or the company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today preliminary top-line results of its ongoing phase 2a trial of sgx302 (synthetic hypericin) for the treatment of mild-to-moderate psoriasis.
SNGX Ratings Summary
SNGX Quant Ranking